014339AA3

Alder Biopharmaceuticals Inc

Could not find a ticker for this position, may be a filing error

A biotechnology company that develops therapeutic antibodies, best known for creating the migraine-prevention medicine eptinezumab (brand name Vyepti), the first such treatment given by IV infusion. Founded in 2004 in Bothell, Washington, by former Celltech researchers, it was later bought by the Danish pharma firm H. Lundbeck and renamed Lundbeck Seattle Biopharmaceuticals. Fun fact: its name comes from the alder tree, a nod to the Pacific Northwest where the company was born.

2.50% Convertible Senior Notes due February 1, 2025